Rodin Therapeutics Applies Insights of Epigenetics to Neurological Disorders
News Jul 01, 2013
Rodin Therapeutics has announced its founding by Atlas Venture and Proteros biostructures. Rodin is founded based on its insight into key epigenetic modulators of CNS function, privileged access to Proteros’ best-in-class structural biology capabilities, and a team with deep CNS drug development and company formation experience.
Rodin secured financing from Atlas Venture and Johnson & Johnson Development Corporation (JJDC).
“The field of cognitive disorders such as Alzheimer’s Disease represents a critical unmet medical need with a large opportunity for new therapeutics,” said Dr. Bruce Booth, Acting CEO of Rodin Therapeutics.
Dr. Booth continued, “We are excited to launch Rodin Therapeutics as a capital efficient vehicle to take a novel, epigenetics guided approach to these diseases.”
The Rodin platform and pipeline is the product of a strategic partnership with Proteros, a leader in structural biology, biophysical profiling and integrated lead discovery.
Proteros’ capabilities enable an orthogonal look at the interactions of small molecules as they bind to key epigenetic targets.
Proteros is a founding shareholder in Rodin, and will offer Rodin privileged access to leading-edge technology and exclusive rights to key targets.
The Rodin team and Proteros scientists will work together to advance the Rodin pipeline and discovery efforts.
Dr. Torsten Neuefeind, CEO of Proteros commented: “We are excited about the founding of Rodin Therapeutics and to join the high caliber team of CNS experts and blue chip investors. This is a further validation of our structure-based discovery platform for a novel neuroscience approach.
Arnd Christ, CFO of Proteros added: “Rodin represents an innovative target focused financing approach to address the interest of all parties involved.”
The Johnson & Johnson Innovation Center in Boston and Janssen Research & Development, LLC, part of the Janssen Pharmaceutical Companies of Johnson & Johnson, will engage in scientific collaboration with Rodin Therapeutics with the goal of sharing knowledge and expertise to advance novel solutions in CNS.
A member of the Boston Innovation Center will participate on the company’s Scientific Advisory Board.
Rodin has assembled a team with deep drug discovery and company creation experience including Martin Jefson PhD, former head of Neuroscience Research at Pfizer (Chief Scientific Officer); Ankit Mahadevia MD, Venture Partner at Atlas Venture (Acting Chief Business Officer); Bruce Booth, PhD, Partner at Atlas Venture (Acting Chief Executive Officer).
Children who are genetically predisposed to overweight, due to common gene variants, can still lose weight by changing their diet and exercise habits. Around 750 children and adolescents with overweight or obesity undergoing lifestyle intervention participated in the study conducted by researchers from the University of Copenhagen and Holbæk Hospital.
Global Experts Meeting on Frontiers in Biosimilars and Biologics Congress
Oct 24 - Oct 26, 2019